SIR, Inhibitors of tumour necrosis factor a (TNF-a; monoclonal antibodies or soluble receptors) have proven their efficacy in the treatment of rheumatoid arthritis (RA) and are currently under investigation in other chronic inflammatory diseases. However, an increase in infectious complications is noticed with these molecules. We report an RA patient who developed haemophagocytic syndrome (HPS) while she was being treated with infliximab.
A 46-yr-old woman had suffered from seropositive RA (American Rheumatism Association criteria) since 1999. Despite active treatment with steroids, methotrexate and sulphasalazine, the disease remained active wdisease activity score (DAS) >4.5x. Treatment with infliximab (3 mgukg) was started in December 2000 with a good clinical and biological effect, allowing termination of steroids and non-steroidal anti-inflammatory drugs. After three perfusions the DAS was 2 and remained so during the following months. The treatment was well tolerated. An episode of urinary tract infection with bacteraemia occurred in April 2001.
Six weeks after the seventh perfusion, she presented at the emergency room with fever, dehydration, weight loss w5 pounds (2.3 kg) in 3 daysx and profound lethargy. RA was quiescent. She had hepatosplenomegaly and pain in the right flank. Biological examinations revealed thrombopenia (16 3 Coagulation tests were within normal ranges, with no element of intravascular coagulopathy (screen for soluble complexes was negative). Urine and blood cultures showed growth of Escherichia coli.
HPS was evoked and confirmed by bone marrow aspiration, which showed numerous macrophages with intracytoplasmic fragments of red blood cells, neutrophils or platelets (Figs 1 and 2 No aetiology other than infection with E. coli and infliximab was found for the HPS. Complement fractions were within normal ranges and the patient had no antinuclear antibodies or anti-DNA or anti-SSAuSSB antibodies. Screening for other infectious diseases (HIV, hepatitis B or C, Plasmodium, herpes virus, Toxoplasma gondii, Epstein-Barr virus, Aspergillus, Cryptococcus and cytomegalovirus) was negative. The chest X-ray was normal; abdominal sonography and CT scanning showed hepatosplenomegaly.
She was treated with intravenous antibiotics and intravenous immunoglobulin (1 gukguday for 2 days) with prompt clinical recovery; biological changes returned to normal within 2 weeks. An exploration of the urinary tract was negative. Infliximab was definitively stopped. HPS is a rare life-threatening complication of inflammatory diseases. TNF-a seems to play a pivotal role in its origin by macrophage activation, and anti-TNF-a therapy could protect against HPS. The role of infliximab in this case is difficult to evaluate. It is known that infliximab can induce multiple infections. In our patient's case, the time course of the infection, which occurred a long time after the last perfusion, may explain the development of HPS related to this infection.
Two types of HPS have been identified. The first is the primary familial HPS of genetic origin (haemophagocytic lymphohistiocytosis). This is a primary and rapidly fatal syndrome of T lymphocyte and macrophage activation and is cured only by bone marrow transplantation. The other type is secondary HPS related to nonspecific activation of macrophages by inflammatory lymphokines. The T lymphocytes involved in this process are of the Th1 subtype. This form of HPS is encountered in situations such as haemopathy, autoimmune diseases and infections (viral, bacterial, fungal etc.).
The occurrence of secondary HPS during infection seems to depend on two elements: the intensity of the infectious event itself (the trigger) and an underlying immune defect (the background). Stephan et al. w1x performed systematic medullary biopsies on 20 patients with septic shock and thrombopenia without previous immunosuppression. Sixty per cent of the patients had histological signs of HPS. For Tsuda w2x, the underlying immune defect could explain the occurrence of severe infectious events and the abnormal cytokine response.
The association of HPS with systemic lupus and Still's disease is well known. Its occurrence in RA patients is infrequent, with few reported cases following severe infections w3-5x.
During HPS, elevation of proinflammatory cytokines is observed-mainly TNF-a, interleukin (IL)-1 and IL-6 but also interferon c w6, 7x-reflecting hyperactivation of macrophages. As TNF-a seems to have a pivotal role, the use of inhibitors of TNF-a to treat this syndrome has been proposed w8x. Others have reported high levels of interferon c or macrophage-colony stimulating factor during HPS w9x.
It is now established that, during treatment with TNF-a inhibitors, there are reductions in the circulating level of bioactive TNF-a and, to a lesser extent, of IL-6 and IL-1 w10x. For interferon c the results are not clear, some papers showing a reduction w11x and others an elevation of interferon c-producing T lymphocytes w12x.
In the present case, the immune defect induced by infliximab was probably responsible for the severe bacterial infection leading to HPS. In our RA patient, the clinical and biological evolution was due to the very active treatment, and the reduction of circulating TNF-a also probably contributed; however, we did not measure circulating cytokines, and a role of interferon c in this case of HPS cannot be ruled out. Another hypothesis is that the severe sepsis led to greatly increased production of TNF-a, so that the circulating level overcame the neutralizing antibody.
In conclusion, we report a case (the first to our knowledge) of HPS in an RA patient treated with infliximab. It is possible that the immunosuppression induced by the anti-TNF-a treatment favoured the occurrence of a severe infectious event, leading to major cytokine production and to the HPS syndrome. Clinicians should be aware of such a complication. 
